PMID- 32346613
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 17
DP  - 2020 Jun 26
TI  - Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies 
      Clinical Implications for Cancer Therapy.
PG  - 241-249
LID - 10.1016/j.omto.2020.03.021 [doi]
AB  - Lung cancer is the most common cause of cancer deaths worldwide, and lung 
      adenocarcinoma (LUAD) is the most common histological subtype. However, the 
      prognostic and predictive outcomes differ because of this cancer type 
      heterogeneity. LUAD subtypes were identified on the basis of the immunogenomic 
      profiling of 29 immune signatures. We named three LUAD subtypes: Immunity High, 
      Immunity Medium, and Immunity Low. The Immunity High subtype was characterized by 
      immune activation, e.g., increased immune scores, elevated stromal scores and the 
      highest infiltration of CD8(+) T cells, and decreased tumor purities. Activated 
      expressions of human leukocyte antigen (HLA) genes, immune checkpoint molecules, 
      and T helper 1 (Th1)/interferon-gamma (IFNgamma) gene signature were also observed in 
      the Immunity High subtype. N (6)-methyladenosine (m(6)A) RNA methylation, 
      associated with cancer initiation and progression, was reduced in the Immunity 
      High subtype. Functional and signaling pathway enrichment analysis further showed 
      that differentially expressed genes between the Immunity High subtype and the 
      other subtypes mainly participated in immune response and some cancer-associated 
      pathways. In addition, the Immunity High subtype exhibited more sensitivity to 
      immunotherapy and chemotherapy. Finally, candidate compounds that aimed at LUAD 
      subtype differentiation were identified. Comprehensively characterizing the LUAD 
      subtypes based on immune signatures may help to provide potential strategies for 
      LUAD treatment.
CI  - (c) 2020 The Author(s).
FAU - Xu, Feng
AU  - Xu F
AD  - Department of Respiratory Medicine, The First Affiliated Hospital of Shantou 
      University Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, 
      P.R. China.
FAU - Chen, Jie-Xin
AU  - Chen JX
AD  - Department of Endocrinology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
FAU - Yang, Xiong-Bin
AU  - Yang XB
AD  - Department of Rheumatology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
FAU - Hong, Xin-Bin
AU  - Hong XB
AD  - Department of Endocrinology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
FAU - Li, Zi-Xiong
AU  - Li ZX
AD  - Department of Rheumatology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
FAU - Lin, Ling
AU  - Lin L
AD  - Department of Rheumatology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
FAU - Chen, Yong-Song
AU  - Chen YS
AD  - Department of Endocrinology, The First Affiliated Hospital of Shantou University 
      Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC7183104
OTO - NOTNLM
OT  - immune response
OT  - immune signatures
OT  - lung adenocarcinoma
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
PMCR- 2020/04/07
CRDT- 2020/04/30 06:00
PHST- 2020/02/23 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
PHST- 2020/04/07 00:00 [pmc-release]
AID - S2372-7705(20)30046-2 [pii]
AID - 10.1016/j.omto.2020.03.021 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2020 Apr 7;17:241-249. doi: 10.1016/j.omto.2020.03.021. 
      eCollection 2020 Jun 26.